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There is currently no cure for malignant melanoma and the best hope for a patient is 
early diagnosis and surgical excision. A promising approach to early cancer diagnosis is 
the use of radiolabeled peptides for tumor imaging. Dr. Quinn's lab has developed a 
cyclized peptide analog of alpha-Melanocyte stimulating hormone called ReCCMSH 
which binds to over expressed melanocortin-1 receptors on the tumor cells. A common 
radioimaging technique in nuclear medicine is positron emission tomography (PET). 
The radionuclide, fluorine-18, is widely used as a labeling agent for PET studies 
because of its 110 minute half life and low energy and is thus a good candidate for 
radiolabeling of our peptide. However, direct fluorination of the peptide is not possible. 
To radiolabel the peptide, a prosthetic group must be developed that can be attached to 
the peptide and act as a fluorine acceptor. This prosthetic group must not alter the 
biological properties of the peptide including receptor affinity, rapid body clearance, and 
absence of side reactions. The organic synthesis of this prosthetic group was the focus 
of my research. Previous attempts at radiolabeling of the conjugated peptide have been 
inefficient multi-step syntheses and thus impractical. For my research, a benzyl 
aldehyde was modified through a series of reactions to create carboxyl-3-cyano-4-
N,N,N-trimethylanilinium triflate. This compound can be coupled to the end of the 
peptide and subsequently radiolabeled in one efficient step. The peptide was 
synthesized via solid phase peptide synthesis and cyclized via rhenium metal 
coordination. The actual radiolabeling of the conjugated peptide along with the in vivo 
biodistribution studies on mice will be pursued over the next academic year.  
 
